The cell-free fetal DNA (cffDNA) test
is a new technology being used to assess the risk of a pregnant woman's developing baby (fetus) against any abnormalities such as chromosome disorder, like Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), or Patau syndrome (trisomy 13). This new technology is being used as an alternative to currently available prenatal tests. It may be used to identify other rare conditions resulting from an extra chromosome or missing piece of chromosome (microdeletion). This new prenatal disorder testing technology is expected to be driven by major factors such as safe and low risk obstetric nature of this technology for prenatal testing coupled with increasing awareness about inherited disorders.
This report identifies the
cell free fatal DNA testing market
size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to cell free fatal DNA testing market.
Globally North America dominated the market for cell free fatal DNA testing in 2015 due to developed medical infrastructure and high occurrence of several disease related to cell free DNA testing. North America is expected to continue its domination and was followed by Europe and Asia-Pacific as the second and third largest markets respectively in 2015. However Asia-Pacific is expected to be the fastest growing market due to technological advancement and changing medical infrastructure in the major economies in the region along with increasing awareness about necessity prenatal testing.
This report on global cell free fatal DNA testing also covers different type of cell free fatal DNA testing available, and market size in various geographical regions.
- On the basis of type of cell free fatal DNA testing this report classifies as follows covering all major types of cell free fatal DNA testing available in the market: Chromosome Number Abnormality Test, Paternal Inherited Disorder Test, Gender Test and Others
- This report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for cell free fatal DNA testing in each of the region.
Sample Companies Profiled in this Report are:
- The Fetal Medicine Centre
- Apollo Path labs
- Ariosa Diagnostics
- Sequenom Laboratories
- Laboratory Corp. of America Holdings